BioMarin Pharmaceutical Inc (BMRN) stock
BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3092% above fair value
$58.51+0.52 (+0.90%)
Close on Nov 17, 2026Market cap $11.33BP/E 154.0Yield –
BioMarin Pharmaceutical r&d expenses
Research and development expenses are spending on new products and technology.
BioMarin Pharmaceutical's R&D Expenses for the twelve months ending Jun 30, 2026 was $987.64M, up 45.6% year over year. For fiscal 2025 it was $921.93M, up 23.4% from the year before. Over ten years it grew 3.8% a year on average. The highest annual figure on record is $921.93M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $921.93M | +23.4% |
| FY2024 | Dec 31, 2024 | $747.18M | +0.1% |
| FY2023 | Dec 31, 2023 | $746.77M | +15.0% |
| FY2022 | Dec 31, 2022 | $649.61M | +3.3% |
| FY2021 | Dec 31, 2021 | $628.79M | +0.1% |
| FY2020 | Dec 31, 2020 | $628.12M | -12.2% |
| FY2019 | Dec 31, 2019 | $715.01M | +2.7% |
| FY2018 | Dec 31, 2018 | $696.33M | +14.0% |
| FY2017 | Dec 31, 2017 | $610.75M | -7.7% |
| FY2016 | Dec 31, 2016 | $661.91M | +4.3% |
| FY2015 | Dec 31, 2015 | $634.81M | +37.5% |
| FY2014 | Dec 31, 2014 | $461.54M | +30.1% |
| FY2013 | Dec 31, 2013 | $354.78M | +17.4% |
| FY2012 | Dec 31, 2012 | $302.22M | +41.0% |
| FY2011 | Dec 31, 2011 | $214.37M | +45.5% |
| FY2010 | Dec 31, 2010 | $147.31M | +28.0% |
| FY2009 | Dec 31, 2009 | $115.12M | +23.4% |
| FY2008 | Dec 31, 2008 | $93.29M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $206.95M | +28.3% |
| Q1 FY2026 | Mar 31, 2026 | $178.80M | +12.6% |
| Q4 FY2025 | Dec 31, 2025 | $192.41M | +10.9% |
| Q3 FY2025 | Sep 30, 2025 | $409.48M | +121.5% |
| Q2 FY2025 | Jun 30, 2025 | $161.31M | -12.2% |
| Q1 FY2025 | Mar 31, 2025 | $158.73M | -22.6% |
| Q4 FY2024 | Dec 31, 2024 | $173.51M | -15.9% |
| Q3 FY2024 | Sep 30, 2024 | $184.90M | -3.4% |
| Q2 FY2024 | Jun 30, 2024 | $183.79M | +3.6% |
| Q1 FY2024 | Mar 31, 2024 | $204.99M | +19.3% |
| Q4 FY2023 | Dec 31, 2023 | $206.25M | +19.4% |
| Q3 FY2023 | Sep 30, 2023 | $191.31M | +21.2% |
| Q2 FY2023 | Jun 30, 2023 | $177.36M | +12.1% |
| Q1 FY2023 | Mar 31, 2023 | $171.85M | +6.8% |
| Q4 FY2022 | Dec 31, 2022 | $172.75M | +7.2% |
| Q3 FY2022 | Sep 30, 2022 | $157.83M | -0.0% |
| Q2 FY2022 | Jun 30, 2022 | $158.19M | -1.8% |
| Q1 FY2022 | Mar 31, 2022 | $160.84M | +8.1% |
| Q4 FY2021 | Dec 31, 2021 | $161.09M | +2.8% |
| Q3 FY2021 | Sep 30, 2021 | $157.87M | +7.4% |
| Q2 FY2021 | Jun 30, 2021 | $161.11M | -11.5% |
| Q1 FY2021 | Mar 31, 2021 | $148.73M | +4.5% |
| Q4 FY2020 | Dec 31, 2020 | $156.67M | -9.3% |
| Q3 FY2020 | Sep 30, 2020 | $147.05M | -15.0% |
| Q2 FY2020 | Jun 30, 2020 | $182.14M | -1.9% |
| Q1 FY2020 | Mar 31, 2020 | $142.26M | -22.5% |
| Q4 FY2019 | Dec 31, 2019 | $172.81M | -1.5% |
| Q3 FY2019 | Sep 30, 2019 | $172.96M | +7.2% |
| Q2 FY2019 | Jun 30, 2019 | $185.64M | +5.7% |
| Q1 FY2019 | Mar 31, 2019 | $183.59M | -0.2% |
| Q4 FY2018 | Dec 31, 2018 | $175.39M | +4.0% |
| Q3 FY2018 | Sep 30, 2018 | $161.41M | +4.7% |
| Q2 FY2018 | Jun 30, 2018 | $175.58M | +22.8% |
| Q1 FY2018 | Mar 31, 2018 | $183.95M | +26.9% |
| Q4 FY2017 | Dec 31, 2017 | $168.61M | -3.8% |
| Q3 FY2017 | Sep 30, 2017 | $154.10M | -4.2% |
| Q2 FY2017 | Jun 30, 2017 | $143.04M | – |
| Q1 FY2017 | Mar 31, 2017 | $145.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $175.24M | – |
| Q3 FY2016 | Sep 30, 2016 | $160.83M | – |
See a number that looks wrong?